Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lonza announced the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza’s focus on growth along the Healthcare Continuum®.
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.
For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.
Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.
Life sciences company eSense-Lab Ltd is pleased to report its preliminary financial results for the year ending 31 December 2018, along with the attached Appendix 4E.
Esperion provided bempedoic acid franchise development program updates and financial results for the fourth quarter and year ended December 31, 2018.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has raised $1,350,500 from private investors.
MDxHealth SA, announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.